Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000234

Drug Information
NameSRT501
SynonymsLS-2146; HMS1569F17; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; KUC104385N; C059514; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; NCGC00024003-04; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; trans-3,4′,5-Trihydroxystilbene; to_000079; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; 3,5,4'-Trihydroxy-trans-stilbene; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; CHEMBL165; HMS1990H15; FT-0082623; MLS001076538; ZINC00006787; SRT-501; MLS002222231; Prestwick2_000508; CPD-83; AC-727; SPECTRUM1502223; 31100-06-8; 3,5,4'-Trihydroxystilbene; (E)-resveratrol; BSPBio_001114; NSC 327430; CHEBI:45713; KSC-10-164; HMS2052I09; CU-01000001503-3; PREVENTION 8 (RESVERATROL); SDCCGMLS-0002998.P003; resveratrol; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; 501-36-0; RM-1812; IDI1_002152; 3,4',5-Trihydroxy-trans-stilbene; trans-3,4',5-trihydroxystilbene; (E)-5-(p-Hydroxystyryl)resorcinol; TL8003323; CID445154; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+; NCGC00024003-00; EU-0101111; HMS1362H15; AC1L9HIC; LUKBXSAWLPMMSZ-OWOJBTEDSA-; R 5010; BPBio1_000479; CHEBI:27881; C14H12O3; SAM001246888; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 3,4',5-Trihydroxystilbene; STL; SGCUT00007; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; BRD-K80738081-001-10-4; BSPBio_003461; I06-0437; 3,4',5-trihydroxy-stilbene; resveratrol-3-sulfate; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; NCGC00017352-07; R0071; SMR000058206; HSDB 7571; cis-resveratrol; RV; SRT 501; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NCGC00017352-17; NCGC00024003-09; BSPBio_000435; MLS000069735; DB02709; NCGC00024003-07; NCGC00024003-11; Lopac0_001111; NCGC00024003-08; C03582; trans-resveratrol; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; BRD-K25591257-001-01-2; S1396_Selleck; NSC327430; NCGC00024003-10; nchembio.281-comp10; 34092_RIEDEL; R5010_SIGMA; MolPort-002-499-801; 3,4',5-Stilbenetriol; BRD-K80738081-001-06-2; Prestwick3_000508; NCGC00024003-06; nchembio.140-comp2; 34092_FLUKA; SRT501; MLS001055357; BB_NC-2570; LMPK13090005; Resvida; MLS002207121; HMS1921N04; Prestwick_619; CPD000058206; NCGC00024003-05; CCRIS 8952; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; HMS1792H15; Resveratrol, E-; Spectrum5_000552; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 533C1DA0-4104-42B5-9D32-9265F40857E4
CompanySirtris Pharma.
IndicationColorectal CancerPhase Ib    
Multiple MyelomaSuspended in Phase IIa    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9
,15-17H/b2-1+
InChIKeyLUKBXSAWLPMMSZ-OWOJBTEDSA-N
Canonical SMILESC1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O    
Isomeric SMILESC1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
CAS NumberCAS 375823-41-9
FormulaC14H12O3
PubChem Compound IDCID 445154.
PubChem Substance IDSID 6374.
ClinicalTrials.govNCT00920556;
NCT00920803;
TargetNAD-dependent deacetylase sirtuin-1Binder[1]
Ref 1CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543